Ascendis Pharma A/S

93.15-1.95-2.05%Vol 475.17K1Y Perf -30.54%
Jun 28th, 2022 16:00 DELAYED
BID36.88 ASK147.52
Open94.47 Previous Close95.10
Pre-Market- After-Market93.15
 - -  - -%
Target Price
148.50 
Analyst Rating
Strong Buy 1.25
Potential %
59.42 
Finscreener Ranking
★★★+     51.28
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     46.74
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     53.33
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
26.95 
Earnings Rating
Strong Buy
Market Cap5.20B 
Earnings Date
11th May 2022
Alpha0.02 Standard Deviation0.14
Beta0.86 

Today's Price Range

91.3794.95

52W Range

61.58178.71

5 Year PE Ratio Range

-17.50-15.50

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
11.23%
1 Month
7.11%
3 Months
-14.59%
6 Months
-29.39%
1 Year
-30.54%
3 Years
-17.41%
5 Years
243.20%
10 Years
-

TickerPriceChg.Chg.%
ASND93.15-1.9500-2.05
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Financial StrengthValueIndustryS&P 500US Markets
10.50
11.80
0.41
0.70
-51.90
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
44.00
-3 158.60
-3 042.50
-3 838.10
-
RevenueValueIndustryS&P 500US Markets
15.57M
0.27
75.38
5.65
Earnings HistoryEstimateReportedSurprise %
Q01 2022-2.25-2.48-10.22
Q04 2021-2.57-2.1416.73
Q03 2021-2.60-1.7333.46
Q02 2021-2.75-3.01-9.45
Q01 2021-2.06-1.4131.55
Q04 2020-1.84-3.15-71.20
Q03 2020-1.88-2.70-43.62
Q02 2020-1.66-2.17-30.72
Earnings Per EndEstimateRevision %Trend
6/2022 QR-2.136.17Positive
9/2022 QR-2.172.69Positive
12/2022 FY-8.86-0.23Negative
12/2023 FY-8.54-12.66Negative
Next Report Date-
Estimated EPS Next Report-2.25
Estimates Count7
EPS Growth Next 5 Years %15.00
Volume Overview
Volume475.17K
Shares Outstanding55.80K
Shares Float55.80M
Trades Count7.72K
Dollar Volume44.10M
Avg. Volume430.27K
Avg. Weekly Volume423.48K
Avg. Monthly Volume371.31K
Avg. Quarterly Volume496.02K

Ascendis Pharma A/S (NASDAQ: ASND) stock closed at 95.1 per share at the end of the most recent trading day (a 4.4% change compared to the prior day closing price) with a volume of 467.48K shares and market capitalization of 5.20B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 330 people. Ascendis Pharma A/S CEO is Jan Moller Mikkelsen.

The one-year performance of Ascendis Pharma A/S stock is -30.54%, while year-to-date (YTD) performance is -29.31%. ASND stock has a five-year performance of 243.2%. Its 52-week range is between 61.5791 and 178.71, which gives ASND stock a 52-week price range ratio of 26.95%

Ascendis Pharma A/S currently has a PE ratio of -9.50, a price-to-book (PB) ratio of 6.76, a price-to-sale (PS) ratio of 347.83, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -38.10%, a ROC of -41.92% and a ROE of -60.49%. The company’s profit margin is -%, its EBITDA margin is -3 042.50%, and its revenue ttm is $15.57 Million , which makes it $0.27 revenue per share.

Of the last four earnings reports from Ascendis Pharma A/S, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-2.25 for the next earnings report. Ascendis Pharma A/S’s next earnings report date is -.

The consensus rating of Wall Street analysts for Ascendis Pharma A/S is Strong Buy (1.25), with a target price of $148.5, which is +59.42% compared to the current price. The earnings rating for Ascendis Pharma A/S stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Ascendis Pharma A/S has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Ascendis Pharma A/S has a Buy technical analysis rating based on Technical Indicators (ADX : 8.35, ATR14 : 5.44, CCI20 : 188.43, Chaikin Money Flow : 0.14, MACD : -0.21, Money Flow Index : 72.63, ROC : 4.28, RSI : 59.49, STOCH (14,3) : 96.32, STOCH RSI : 1.00, UO : 60.04, Williams %R : -3.68), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Ascendis Pharma A/S in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (80.00 %)
8 (80.00 %)
8 (80.00 %)
Moderate Buy
1 (10.00 %)
1 (10.00 %)
1 (10.00 %)
Hold
1 (10.00 %)
1 (10.00 %)
1 (10.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.25
Strong Buy
1.25

Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others.

CEO: Jan Moller Mikkelsen

Telephone: +45 70222244

Address: Tuborg Boulevard 12, Hellerup DK-2900, , DK

Number of employees: 330

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

70%30%

Bearish Bullish

74%26%

News

Stocktwits